Analysis of the relative costs and effectiveness of primary angioplasty versus tissue-type plasminogen activator: the Primary Angioplasty in Myocardial Infarction (PAMI) trial. The PAMI Trial Investigators

Cardiovascular Institute, El Camino Hospital, Mountain View, California 94040, USA.

OBJECTIVES: We sought to determine the relative cost and effectiveness of two different reperfusion modalities in patients with acute myocardial infarction (AMI). BACKGROUND: Recent studies have found superior clinical outcomes after reperfusion by primary percutaneous transluminal coronary angioplasty (PTCA) compared with thrombolytic therapy. The high up-front costs of cardiac catheterization may diminish the relative advantages of this invasive strategy. METHODS: Detailed in-hospital charge data were available from all 358 patients with AMI randomized to tissue-type plasminogen activator (t-PA) or primary PTCA in the United States from the Primary Angioplasty in Myocardial Infarction trial. Resource consumption during late follow-up was estimated by assessment of major clinical events and functional status. RESULTS: Compared with t-PA, primary PTCA resulted in reduced rates of in-hospital mortality (2.3% vs. 7.2%, p = 0.03), reinfarction (2.8% vs. 7.2%, p = 0.06), recurrent ischemia (11.3% vs. 28.7%, p < 0.0001) and stroke (0% vs. 3.9%, p = 0.02) and a shorter hospital stay (7.6 +/- 3.3 days vs. 8.4 +/- 4.7 days, p = 0.04). Despite the initial costs of cardiac catheterization in all patients with the invasive strategy, total mean (+/- SD) hospital charges were $3,436 lower per patient with PTCA than with t-PA ($23,468 +/- $13,410 vs. $26,904 +/- $18,246, p = 0.04), primarily due to the reduction in adverse in-hospital outcomes. However, professional fees were higher after primary PTCA ($4,185 +/- $3,183 vs. $3,322 +/- $2,728, p = 0.001), and thus total charges, although favoring PTCA, were not significantly different ($27,653 +/- $13,709 vs. $30,227 +/- 18,903, p = 0.21). At a mean follow-up time of 2.1 +/- 0.7 years, no major differences in postdischarge events or New York Heart Association functional class were present between PTCA- and t-PA-treated patients, suggesting similar late resource consumption. Including in-hospital events, 83% of PTCA-treated patients were alive and free of reinfarction at late follow-up, compared with 74% of t-PA-treated patients (p = 0.06). CONCLUSIONS: Compared with t-PA, reperfusion by primary PTCA improves clinical outcomes with similar or reduced costs. These findings have important clinical implications in an increasingly cost-conscious health care environment.

This article has been cited by other articles:

				W. E. Boden, K. Eagle, and C. B. Granger Reperfusion Strategies in Acute ST-Segment Elevation Myocardial Infarction: A Comprehensive Review of Contemporary Management Options J. Am. Coll. Cardiol., September 4, 2007; 50(10): 917 - 929. [Abstract] [Full Text] [PDF]

				E. C. Keeley and L. D. Hillis Primary PCI for Myocardial Infarction with ST-Segment Elevation N. Engl. J. Med., January 4, 2007; 356(1): 47 - 54. [Full Text] [PDF]

				K D Dawkins, T Gershlick, M de Belder, A Chauhan, G Venn, P Schofield, D Smith, J Watkins, H H Gray, and Joint Working Group on Percutaneous Coronary Inter Percutaneous coronary intervention: recommendations for good practice and training Heart, December 1, 2005; 91(suppl_6): vi1 - vi27. [Abstract] [Full Text] [PDF]

				N Melikian, K Morgan, and K J Beatt Can the published cost analysis data for delivery of an efficient primary angioplasty service be applied to the modern National Health Service? Heart, October 1, 2005; 91(10): 1262 - 1264. [Abstract] [Full Text] [PDF]

				P M Schofield Acute myocardial infarction: the case for pre-hospital thrombolysis with or without percutaneous coronary intervention Heart, June 1, 2005; 91(suppl_3): iii7 - iii11. [Full Text] [PDF]

				J. Machecourt, E. Bonnefoy, G. Vanzetto, P. Motreff, S. Marliere, A. Leizorovicz, B. Allenet, J. M. Lacroute, J. Cassagnes, and P. Touboul Primary angioplasty is cost-minimizing compared with pre-hospital thrombolysis for patients within 60 min of a percutaneous coronary intervention center: The Comparison of Angioplasty and Pre-hospital Thrombolysis in Acute Myocardial Infarction (CAPTIM) cost-efficacy sub-study J. Am. Coll. Cardiol., February 15, 2005; 45(4): 515 - 524. [Abstract] [Full Text] [PDF]

				V. M.G. Legrand, P. W. Serruys, F. Unger, B. A. van Hout, M. C.M. Vrolix, G. M.P. Fransen, T. T. Nielsen, P. K. Paulsen, R. S. Gomes, J. M.G. de Queiroz e Melo, et al. Three-Year Outcome After Coronary Stenting Versus Bypass Surgery for the Treatment of Multivessel Disease Circulation, March 9, 2004; 109(9): 1114 - 1120. [Abstract] [Full Text] [PDF]

				M. R. Le May, R. F. Davies, M. Labinaz, H. Sherrard, J.-F. Marquis, L. A. Laramee, E. R. O'Brien, W. L. Williams, R. S. Beanlands, G. Nichol, et al. Hospitalization Costs of Primary Stenting Versus Thrombolysis in Acute Myocardial Infarction: Cost Analysis of the Canadian STAT Study Circulation, November 25, 2003; 108(21): 2624 - 2630. [Abstract] [Full Text] [PDF]

				W. A. Ghali, C. R. Donaldson, M. L. Knudtson, S. J. Lewis, C. J. Maxwell, and J. V. Tu Rising to the challenge: transforming the treatment of ST-segment elevation myocardial infarction Can. Med. Assoc. J., July 8, 2003; 169(1): 35 - 37. [Full Text] [PDF]

				T. Aversano, L. T. Aversano, E. Passamani, G. L. Knatterud, M. L. Terrin, D. O. Williams, S. A. Forman, and for the Atlantic Cardiovascular Patient Outcomes R Thrombolytic Therapy vs Primary Percutaneous Coronary Intervention for Myocardial Infarction in Patients Presenting to Hospitals Without On-site Cardiac Surgery: A Randomized Controlled Trial JAMA, April 17, 2002; 287(15): 1943 - 1951. [Abstract] [Full Text] [PDF]

				C. P. Cannon Primary Percutaneous Coronary Intervention for All? JAMA, April 17, 2002; 287(15): 1987 - 1989. [Full Text] [PDF]

				G. W. Stone, C. L. Grines, D. A. Cox, E. Garcia, J. E. Tcheng, J. J. Griffin, G. Guagliumi, T. Stuckey, M. Turco, J. D. Carroll, et al. Comparison of Angioplasty with Stenting, with or without Abciximab, in Acute Myocardial Infarction N. Engl. J. Med., March 28, 2002; 346(13): 957 - 966. [Abstract] [Full Text] [PDF]

				J. Iemura, H. Oku, M. Otaki, H. Kitayama, T. Inoue, and T. Kaneda Surgical strategy for left ventricular free wall rupture after acute myocardial infarction Ann. Thorac. Surg., January 1, 2001; 71(1): 201 - 204. [Abstract] [Full Text] [PDF]

				T. P. Wharton Jr., N. Sinclair McNamara, F. A. Fedele, M. I. Jacobs, A. R. Gladstone, and E. J. Funk Reply J. Am. Coll. Cardiol., July 1, 2000; 36(1): 301 - 303. [Full Text] [PDF]

				M A DE BELDER and J A HALL Infarct angioplasty Heart, October 1, 1999; 82(4): 399 - 401. [Full Text] [PDF]

				T. Kawamoto, K. Yoshida, T. Akasaka, T. Hozumi, T. Takagi, S. Kaji, and Y. Ueda Can Coronary Blood Flow Velocity Pattern After Primary Percutaneous Transluminal Coronary Angiography Predict Recovery of Regional Left Ventricular Function in Patients With Acute Myocardial Infarction? Circulation, July 27, 1999; 100(4): 339 - 345. [Abstract] [Full Text] [PDF]

				T. P. Wharton Jr., N. S. McNamara, F. A. Fedele, M. I. Jacobs, A. R. Gladstone, and E. J. Funk Primary angioplasty for the treatment of acute myocardial infarction: experience at two community hospitals without cardiac surgery J. Am. Coll. Cardiol., April 1, 1999; 33(5): 1257 - 1265. [Abstract] [Full Text] [PDF]

				G. W. Stone Primary Stenting in Acute Myocardial Infarction : The Promise and the Proof Circulation, June 30, 1998; 97(25): 2482 - 2485. [Full Text] [PDF]

				PTCA OR THROMBOLYSIS -- WHICH COSTS MORE FOR ACUTE MI? Journal Watch (General), April 15, 1997; 1997(415): 7 - 7. [Full Text]